Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2CNS 2NET 1Myeloid 1Lymphoid 1Genitourinary 1Gastrointestinal 1Endocrine 1

Conditions

Fallopian Tube Neoplasms 10Ovarian Neoplasms 7Endometrial Neoplasms 5Breast Neoplasms 4Prostatic Neoplasms 3Parkinson Disease 4, Autosomal Dominant Lewy Body 3Pancreatic Neoplasms 3Neoplasm Metastasis 3Triple Negative Breast Neoplasms 2Osteosarcoma 2Neuroendocrine Tumors 2Neuroblastoma 2Neoplasms 2Medulloblastoma 2Lymphoma, Non-Hodgkin 2Glioma 2Ependymoma 2Xanthogranuloma, Juvenile 1Wilms Tumor 1Urinary Bladder Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Sarcoma, Synovial 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Rhabdoid Tumor 1Recurrent Ovarian High Grade Serous Adenocarcinoma 1Recurrence 1

Interventions

Magnetic Resonance Spectroscopy 6X-Rays 5Phantoms, Imaging 5Nuclear Medicine Department, Hospital 5Specimen Handling 4Biopsy 4ulixertinib 2tipifarnib 2selpercatinib 2olaparib 2larotrectinib 2ivosidenib 2erdafitinib 2ensartinib 2Vincristine 2Temozolomide 2Cyclophosphamide 2Cisplatin 2tazemetostat 1palbociclib 1lutetium Lu 177 dotatate 1Vemurafenib 1Vascular Endothelial Growth Factor A 1Triiodothyronine 1Thiotepa 1Radiotherapy 1Radiation 1Platinum 1Pharmacogenomic Variants 1Nivolumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Medulloblastoma × olaparib × 30 days × Clear all
NCT06607692 2026-06-04

LUPARPED

Fundación de investigación HM

Phase 1/2 Recruiting
25 enrolled
CNSEndocrineNETSarcoma

Adrenal Cortex Neoplasms, Adrenal Gland Neoplasms, Ependymoma, Glioblastoma, Glioma, Medulloblastoma, Meningioma, Neuroblastoma, Paraganglioma, Pheochromocytoma, Recurrence, Osteosarcoma, Sarcoma, Synovial, Esthesioneuroblastoma, Olfactory, Neuroendocrine Tumors

NCT03155620 2026-06-01

Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
1,377 enrolled 10 charts
CNSGastrointestinalGenitourinaryLymphoidMyeloidSarcoma

Ependymoma, Glioma, Histiocytosis, Langerhans-Cell, Lymphoma, Non-Hodgkin, Medulloblastoma, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Xanthogranuloma, Juvenile, Central Nervous System Neoplasms, Hepatoblastoma, Neuroectodermal Tumors, Primitive, Peripheral, Rhabdoid Tumor, Histiocytic Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡